Cannabidiorcol

{{Short description|Phytocannabinoid}}

{{Drugbox

| IUPAC_name = 5-methyl-2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene-1,3-diol

| image = cannabidiorcol.png

| image_class = skin-invert-image

| width = 220

| tradename =

| CAS_number = 35482-50-9

| UNII = 259WR5E2RF

| ChemSpiderID = 17590348

| PubChem = 16657068

| C=17 | H=22 | O=2

| StdInChI=1S/C17H22O2/c1-10(2)13-6-5-11(3)7-14(13)17-15(18)8-12(4)9-16(17)19/h7-9,13-14,18-19H,1,5-6H2,2-4H3/t13-,14+/m0/s1

| StdInChIKey = GKVOVXWEBSQJPA-UONOGXRCSA-N

| smiles = CC1=C[C@H]([C@@H](CC1)C(=C)C)C2=C(C=C(C=C2O)C)O

}}

Cannabidiorcol (CBDO, CBD-C1, O-1821) is a phytocannabinoid found naturally in Cannabis in trace concentrations. It is related to cannabidiol, with the pentyl side chain shortened to a methyl group. Cannabidiorcol has low affinity for cannabinoid receptors and is mainly active as an agonist of the TRPV2 cation channel, through which it produces antiinflammatory effects,{{cite journal | vauthors = Laragione T, Harris C, Gulko PS | title = Combination therapy of a TRPV2 agonist with a TNF inhibitor achieves sustained suppression of disease severity and reduced joint damage | journal = Clinical and Experimental Immunology | volume = 211 | issue = 3 | pages = 233–238 | date = March 2023 | pmid = 36571199 | pmc = 10038320 | doi = 10.1093/cei/uxac124 }} but can also promote tumorigenesis at high concentrations.{{cite journal | vauthors = Huang R, Li S, Tian C, Zhou P, Zhao H, Xie W, Xiao J, Wang L, Habimana JD, Lin Z, Yang Y, Cheng N, Li Z | display-authors = 6 | title = Thermal stress involved in TRPV2 promotes tumorigenesis through the pathways of HSP70/27 and PI3K/Akt/mTOR in esophageal squamous cell carcinoma | journal = British Journal of Cancer | volume = 127 | issue = 8 | pages = 1424–1439 | date = November 2022 | pmid = 35896815 | doi = 10.1038/s41416-022-01896-2 | pmc = 9553907 }}